Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arterial infusion irinotecan liposome plus 5-FU/LV with or without bevacizumab in first-line metastatic colorectal cancer with liver or lung metastases
ChiCTR2400081497Phase 4Recruiting
- Sponsor
- Lishui City Central Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome, fluorouracil, folinic acid and bevacizumab in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by Lishui City Central Hospital. Primary endpoint: Objective response rate. Started Mar 2024; status: recruiting.
02
Drugs
irinotecan liposomefluorouracilfolinic acidbevacizumab
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400081497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081497.